Shoshana H Ballew1, Yan Chen2, Natalie R Daya2, Job G Godino3, B Gwen Windham4, Mara McAdams-DeMarco2, Josef Coresh2, Elizabeth Selvin2, Morgan E Grams5. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. Electronic address: sballew1@jhmi.edu. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 3. Center for Wireless and Population Health Systems, Department of Family Medicine and Public Health, University of California San Diego, San Diego, CA. 4. Division of Geriatrics, Department of Medicine, University of Mississippi Medical Center, Jackson, MS. 5. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Division of Nephrology, Department of Medicine, Johns Hopkins University, Baltimore, MD.
Abstract
BACKGROUND: Frail individuals are at increased risk for poor outcomes, including adverse drug events. Kidney function is often compromised in frailty and is a key consideration in medication choice and dosing; however, creatinine-based measures of kidney function may be biased in frail individuals. STUDY DESIGN: Observational study. SETTING & PARTICIPANTS: 4,987 community-dwelling older men and women with complete data who participated in visit 5 of the Atherosclerosis Risk in Communities (ARIC) Study (2011-2013). PREDICTORS: Kidney measures included glomerular filtration rate (GFR) estimated using serum creatinine (eGFRcr) and serum cystatin C level (eGFRcys) and urine albumin-creatinine ratio. OUTCOME: Frailty, defined using established criteria of 3 or more frailty characteristics (weight loss, slowness, exhaustion, weakness, and low physical activity). RESULTS: 341 (7%) participants were classified as frail, 1,475 (30%) had eGFRcr<60mL/min/1.73m2, 2,480 (50%) had eGFRcys<60mL/min/1.73m2, and 1,006 (20%) had albuminuria with albumin excretion ≥ 30mg/g. Among frail participants, prevalences of eGFRcr and eGFRcys<60mL/min/1.73m2 were 45% and 77%, respectively. Adjusted for covariates, frailty showed a moderate association with eGFRcr and a strong association with eGFRcys and albumin-creatinine ratio. Frail individuals with eGFRcr of 60 to <75mL/min/1.73m2 were frequently reclassified to lower eGFR categories using eGFRcys (49% to 45-<60, 32% to 30-<45, and 3% to <30mL/min/1.73m2). Hyperpolypharmacy (taking ≥10 classes of medications) was more common in frail individuals (54% vs 38% of nonfrail), including classes requiring kidney clearance (eg, digoxin) and associated with falls and subsequent complications (eg, hypnotic/sedatives and anticoagulants). LIMITATIONS: Cross-sectional study design. CONCLUSIONS: Frail individuals had a high prevalence of reduced kidney function, with large discrepancies when reduced kidney function was classified by eGFRcys versus eGFRcr. Given the substantial medication burden and uncertainty in chronic kidney disease classification, confirmation of kidney function with alternative biomarkers may be warranted to ensure careful prescribing practices in this vulnerable population.
BACKGROUND: Frail individuals are at increased risk for poor outcomes, including adverse drug events. Kidney function is often compromised in frailty and is a key consideration in medication choice and dosing; however, creatinine-based measures of kidney function may be biased in frail individuals. STUDY DESIGN: Observational study. SETTING & PARTICIPANTS: 4,987 community-dwelling older men and women with complete data who participated in visit 5 of the Atherosclerosis Risk in Communities (ARIC) Study (2011-2013). PREDICTORS: Kidney measures included glomerular filtration rate (GFR) estimated using serum creatinine (eGFRcr) and serum cystatin C level (eGFRcys) and urine albumin-creatinine ratio. OUTCOME: Frailty, defined using established criteria of 3 or more frailty characteristics (weight loss, slowness, exhaustion, weakness, and low physical activity). RESULTS: 341 (7%) participants were classified as frail, 1,475 (30%) had eGFRcr<60mL/min/1.73m2, 2,480 (50%) had eGFRcys<60mL/min/1.73m2, and 1,006 (20%) had albuminuria with albumin excretion ≥ 30mg/g. Among frail participants, prevalences of eGFRcr and eGFRcys<60mL/min/1.73m2 were 45% and 77%, respectively. Adjusted for covariates, frailty showed a moderate association with eGFRcr and a strong association with eGFRcys and albumin-creatinine ratio. Frail individuals with eGFRcr of 60 to <75mL/min/1.73m2 were frequently reclassified to lower eGFR categories using eGFRcys (49% to 45-<60, 32% to 30-<45, and 3% to <30mL/min/1.73m2). Hyperpolypharmacy (taking ≥10 classes of medications) was more common in frail individuals (54% vs 38% of nonfrail), including classes requiring kidney clearance (eg, digoxin) and associated with falls and subsequent complications (eg, hypnotic/sedatives and anticoagulants). LIMITATIONS: Cross-sectional study design. CONCLUSIONS: Frail individuals had a high prevalence of reduced kidney function, with large discrepancies when reduced kidney function was classified by eGFRcys versus eGFRcr. Given the substantial medication burden and uncertainty in chronic kidney disease classification, confirmation of kidney function with alternative biomarkers may be warranted to ensure careful prescribing practices in this vulnerable population.
Authors: Ron T Gansevoort; Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh Journal: Kidney Int Date: 2011-02-02 Impact factor: 10.612
Authors: Alexander Bennett; Danijela Gnjidic; Mark Gillett; Peter Carroll; Slade Matthews; Kristina Johnell; Johan Fastbom; Sarah Hilmer Journal: Drugs Aging Date: 2014-03 Impact factor: 3.923
Authors: Anna M Kucharska-Newton; Priya Palta; Sheila Burgard; Michael E Griswold; Jennifer L Lund; Benjamin D Capistrant; Stephen B Kritchevsky; Karen Bandeen-Roche; B Gwen Windham Journal: J Gerontol A Biol Sci Med Sci Date: 2017-03-01 Impact factor: 6.053
Authors: Michael G Shlipak; Kunihiro Matsushita; Johan Ärnlöv; Lesley A Inker; Ronit Katz; Kevan R Polkinghorne; Dietrich Rothenbacher; Mark J Sarnak; Brad C Astor; Josef Coresh; Andrew S Levey; Ron T Gansevoort Journal: N Engl J Med Date: 2013-09-05 Impact factor: 91.245
Authors: D Gnjidic; S N Hilmer; F M Blyth; V Naganathan; R G Cumming; D J Handelsman; A J McLachlan; D R Abernethy; E Banks; D G Le Couteur Journal: Clin Pharmacol Ther Date: 2012-02-01 Impact factor: 6.875
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Natalie Daya; Annie Voskertchian; Andrea L C Schneider; Shoshana Ballew; Mara McAdams DeMarco; Josef Coresh; Lawrence J Appel; Elizabeth Selvin; Morgan E Grams Journal: Am J Kidney Dis Date: 2015-08-04 Impact factor: 8.860
Authors: Christina Hao Wang; Anna D Rubinsky; Tracy Minichiello; Michael G Shlipak; Erika Leemann Price Journal: J Gen Intern Med Date: 2018-05-31 Impact factor: 5.128
Authors: M Gutiérrez-Valencia; M Izquierdo; M Cesari; Á Casas-Herrero; M Inzitari; N Martínez-Velilla Journal: Br J Clin Pharmacol Date: 2018-05-03 Impact factor: 4.335
Authors: Eugenia Wong; Shoshana H Ballew; Natalie Daya; Junichi Ishigami; Casey M Rebholz; Kunihiro Matsushita; Morgan E Grams; Josef Coresh Journal: Am J Nephrol Date: 2019-07-16 Impact factor: 3.754
Authors: Josef Coresh; Lesley A Inker; Yingying Sang; Jingsha Chen; Tariq Shafi; Wendy S Post; Michael G Shlipak; Lisa Ford; Kelli Goodman; Regis Perichon; Tom Greene; Andrew S Levey Journal: Nephrol Dial Transplant Date: 2019-05-01 Impact factor: 5.992